280 related articles for article (PubMed ID: 20164297)
1. Progesterone receptor membrane component 1 (Pgrmc1): a heme-1 domain protein that promotes tumorigenesis and is inhibited by a small molecule.
Ahmed IS; Rohe HJ; Twist KE; Mattingly MN; Craven RJ
J Pharmacol Exp Ther; 2010 May; 333(2):564-73. PubMed ID: 20164297
[TBL] [Abstract][Full Text] [Related]
2. Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells.
Neubauer H; Adam G; Seeger H; Mueck AO; Solomayer E; Wallwiener D; Cahill MA; Fehm T
Climacteric; 2009 Jun; 12(3):230-9. PubMed ID: 19340614
[TBL] [Abstract][Full Text] [Related]
3. PGRMC1 (progesterone receptor membrane component 1): a targetable protein with multiple functions in steroid signaling, P450 activation and drug binding.
Rohe HJ; Ahmed IS; Twist KE; Craven RJ
Pharmacol Ther; 2009 Jan; 121(1):14-9. PubMed ID: 18992768
[TBL] [Abstract][Full Text] [Related]
4. S2R(Pgrmc1): the cytochrome-related sigma-2 receptor that regulates lipid and drug metabolism and hormone signaling.
Ahmed IS; Chamberlain C; Craven RJ
Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):361-70. PubMed ID: 22292588
[TBL] [Abstract][Full Text] [Related]
5. Hpr6 (heme-1 domain protein) regulates the susceptibility of cancer cells to chemotherapeutic drugs.
Crudden G; Chitti RE; Craven RJ
J Pharmacol Exp Ther; 2006 Jan; 316(1):448-55. PubMed ID: 16234411
[TBL] [Abstract][Full Text] [Related]
6. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
7. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
8. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo.
Moore LD; Isayeva T; Siegal GP; Ponnazhagan S
Clin Cancer Res; 2008 Aug; 14(15):4961-70. PubMed ID: 18676771
[TBL] [Abstract][Full Text] [Related]
9. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
Dong AQ; Kong MJ; Ma ZY; Qian JF; Fan JQ; Xu XH
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1506-9. PubMed ID: 17785094
[TBL] [Abstract][Full Text] [Related]
10. p53 Cooperates berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo.
Katiyar SK; Meeran SM; Katiyar N; Akhtar S
Mol Carcinog; 2009 Jan; 48(1):24-37. PubMed ID: 18459128
[TBL] [Abstract][Full Text] [Related]
11. Involvement of let-7/miR-98 microRNAs in the regulation of progesterone receptor membrane component 1 expression in ovarian cancer cells.
Wendler A; Keller D; Albrecht C; Peluso JJ; Wehling M
Oncol Rep; 2011 Jan; 25(1):273-9. PubMed ID: 21109987
[TBL] [Abstract][Full Text] [Related]
12. Progesterone receptor in non-small cell lung cancer--a potent prognostic factor and possible target for endocrine therapy.
Ishibashi H; Suzuki T; Suzuki S; Niikawa H; Lu L; Miki Y; Moriya T; Hayashi S; Handa M; Kondo T; Sasano H
Cancer Res; 2005 Jul; 65(14):6450-8. PubMed ID: 16024650
[TBL] [Abstract][Full Text] [Related]
13. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
14. Elevated progesterone receptor membrane component 1/sigma-2 receptor levels in lung tumors and plasma from lung cancer patients.
Mir SU; Ahmed IS; Arnold S; Craven RJ
Int J Cancer; 2012 Jul; 131(2):E1-9. PubMed ID: 21918976
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner.
Krysan K; Reckamp KL; Dalwadi H; Sharma S; Rozengurt E; Dohadwala M; Dubinett SM
Cancer Res; 2005 Jul; 65(14):6275-81. PubMed ID: 16024629
[TBL] [Abstract][Full Text] [Related]
16. In vitro inhibition of SKOV-3 cell migration as a distinctive feature of progesterone receptor membrane component type 2 versus type 1.
Albrecht C; Huck V; Wehling M; Wendler A
Steroids; 2012 Dec; 77(14):1543-50. PubMed ID: 23064006
[TBL] [Abstract][Full Text] [Related]
17. Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity.
Ahmed IS; Rohe HJ; Twist KE; Craven RJ
J Biol Chem; 2010 Aug; 285(32):24775-82. PubMed ID: 20538600
[TBL] [Abstract][Full Text] [Related]
18. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide.
Yang L; Mashima T; Sato S; Mochizuki M; Sakamoto H; Yamori T; Oh-Hara T; Tsuruo T
Cancer Res; 2003 Feb; 63(4):831-7. PubMed ID: 12591734
[TBL] [Abstract][Full Text] [Related]
19. Progesterone Receptor Membrane Component 1 and its Accomplice: Emerging Therapeutic Targets in Lung Cancer.
Solairaja S; Ramalingam S; Dunna NR; Venkatabalasubramanian S
Endocr Metab Immune Disord Drug Targets; 2022; 22(6):601-611. PubMed ID: 34847852
[TBL] [Abstract][Full Text] [Related]
20. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
Ma PC; Kijima T; Maulik G; Fox EA; Sattler M; Griffin JD; Johnson BE; Salgia R
Cancer Res; 2003 Oct; 63(19):6272-81. PubMed ID: 14559814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
